Delcath Systems (OTC:DCTH) said today that it won medical device approval for its Chemosat hepatic delivery system from the national health authority in Brazil.
The New York-based company plans to market and sell Chemosat in Brazil for the percutaneous intra-arterial administration of melphalan hydrochloride to the liver with subsequent extracorporeal filtration of blood.
Get the full story at our sister site, Drug Delivery Business News.
The post Delcath wins approval for Chemosat in Brazil appeared first on MassDevice.
from MassDevice http://bit.ly/2E4LYIQ
Cap comentari:
Publica un comentari a l'entrada